Literature DB >> 10992445

Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

E L Munson1, B K Du Chateau, D A Jobe, S D Lovrich, S M Callister, R F Schell.   

Abstract

Borreliacidal antibody production is one of several parameters for establishing the effectiveness of Borrelia burgdorferi vaccines. The production of borreliacidal antibody was studied in vitro by culturing immune lymph node cells with macrophages and B. burgdorferi. We showed that borreliacidal antibody, directed primarily against outer surface protein A (OspA), was readily produced by lymph node cells obtained from C3H/HeJ mice vaccinated with formalin-inactivated B. burgdorferi in aluminum hydroxide, but not recombinant OspA. Anti-OspA borreliacidal antibody was detected in supernatants of cultures of lymph node cells obtained on day 7 after vaccination, peaked on day 17, and rapidly declined. The borreliacidal activity was attributable to immunoglobulin G1 (IgG1), IgG2a, and IgG2b antibodies. When lymph node cells were treated with interleukin-4 (IL-4), production of borreliacidal antibody was inhibited but was unaffected by treatment with anti-IL-4 antibodies. These results suggest that other cytokines, but not IL-4, are mainly responsible for production of the secondary borreliacidal antibody response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992445      PMCID: PMC101497          DOI: 10.1128/IAI.68.10.5496-5501.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Protection of mice against the Lyme disease agent by immunizing with recombinant OspA.

Authors:  E Fikrig; S W Barthold; F S Kantor; R A Flavell
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

2.  Occurrence of severe destructive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi.

Authors:  C L Croke; E L Munson; S D Lovrich; J A Christopherson; M C Remington; D M England; S M Callister; R F Schell
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Antibody response in Lyme disease: evaluation of diagnostic tests.

Authors:  J E Craft; R L Grodzicki; A C Steere
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

4.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

5.  Interleukin-4 enhances anti-IgM stimulation of B cells by improving cell viability and by increasing the sensitivity of B cells to the anti-IgM signal.

Authors:  P D Hodgkin; N F Go; J E Cupp; M Howard
Journal:  Cell Immunol       Date:  1991-04-15       Impact factor: 4.868

6.  Effects of bovine serum albumin on the ability of Barbour-Stoenner-Kelly medium to detect Borrelia burgdorferi.

Authors:  S M Callister; K L Case; W A Agger; R F Schell; R C Johnson; J L Ellingson
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

Review 7.  B-cell stimulatory factor-1/interleukin 4.

Authors:  W E Paul; J Ohara
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

8.  Murine B-cell stimulatory factor 1 (interleukin 4) increases expression of the Fc receptor for IgE on mouse B cells.

Authors:  S A Hudak; S O Gollnick; D H Conrad; M R Kehry
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

9.  Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance.

Authors:  Y Liu; C A Janeway
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

10.  Isolation and cultivation of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  7 in total

1.  Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody.

Authors:  M C Remington; E L Munson; S M Callister; M L Molitor; J A Christopherson; D J DeCoster; S D Lovrich; R F Schell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro.

Authors:  Erik L Munson; Dean T Nardelli; K H Kevin Luk; Monica C Remington; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-01

3.  New Zealand White Rabbits Effectively Clear Borrelia burgdorferi B31 despite the Bacterium's Functional vlsE Antigenic Variation System.

Authors:  Maliha Batool; Andrew E Hillhouse; Yurij Ionov; Kelli J Kochan; Fatemeh Mohebbi; George Stoica; David W Threadgill; Alex Zelikovsky; Suryakant D Waghela; Dominique J Wiener; Artem S Rogovskyy
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

4.  Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Authors:  Erik L Munson; Brian K Du Chateau; Jani R Jensen; Steven M Callister; David J DeCoster; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

5.  Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice.

Authors:  Erik L Munson; David J DeCoster; Dean T Nardelli; Douglas M England; Steven M Callister; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

Review 6.  Hamster and murine models of severe destructive Lyme arthritis.

Authors:  Erik Munson; Dean T Nardelli; Brian K Du Chateau; Steven M Callister; Ronald F Schell
Journal:  Clin Dev Immunol       Date:  2012-02-22

7.  The Position of His-Tag in Recombinant OspC and Application of Various Adjuvants Affects the Intensity and Quality of Specific Antibody Response after Immunization of Experimental Mice.

Authors:  Michal Krupka; Josef Masek; Lucia Barkocziova; Pavlina Turanek Knotigova; Pavel Kulich; Jana Plockova; Robert Lukac; Eliska Bartheldyova; Stepan Koudelka; Radka Chaloupkova; Marek Sebela; Daniel Zyka; Ladislav Droz; Roman Effenberg; Miroslav Ledvina; Andrew D Miller; Jaroslav Turanek; Milan Raska
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.